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Background:MDM2 uses a dual-site mechanism to ubiquitinate p53, involving the acidic domain.
Results:MDM2 acid domain binds NUMB and is critical for NUMB ubiquitination.
Conclusion: Small molecule ligands that target the acid domain of MDM2 stabilize Numb and activate tumor suppressor
activities of p53 in cells.
Significance: NUMB regulates steady-state levels of p53 in cells by disrupting p53-MDM2 acidic domain interactions.
The E3 ubiquitin ligase, MDM2, uses a dual-site mechanism
to ubiquitinate and degrade the tumor suppressor protein p53,
involving interactions with the N-terminal hydrophobic pocket
and the acidic domain of MDM2. The results presented here
demonstrate that MDM2 also uses this same dual-site mecha-
nism to bind to the cell fate determinant NUMB with both the
N-terminal hydrophobic pocket and the acidic domain of
MDM2 also involved in forming the interaction with NUMB.
Furthermore, the acidic domain interactions are crucial for
MDM2-mediated ubiquitination of NUMB. Contrary to p53,
where two separate domains form the interface withMDM2, only
one region within the phosphotyrosine binding domain of NUMB
(amino acids 113–148) mediates binding to both these regions of
MDM2. By binding to both domains on MDM2, NUMB disrupts
the MDM2-p53 complex and MDM2-catalyzed ubiquitination of
p53. Therefore, we have identified the mechanism NUMB uses to
regulate the steady-state levels of the p53 in cells. By targeting the
acidicdomainofMDM2usingaciddomain-binding ligandswecan
overcome MDM2-mediated ubiquitination and degradation of
NUMB impactingon the stabilizationof p53 in cells. Furthermore,
deliveryofMDM2aciddomain-binding ligands tocancercellspro-
motes p53-dependent growth arrest and the induction of apopto-
sis. This highlights the dual-sitemechanism ofMDM2 on another
physiological substrate and identifies the acid domain as well as N
terminus as a potential target for small molecules that inhibit
MDM2.
Murine doubleminute 2 (MDM2)2 is amajor regulator of the
p53 tumor suppressor protein (1). MDM2 attenuates the tran-
scriptional activity of p53 (2, 3) and regulates the levels of p53 in
cells by acting as an E3 ligase for the ubiquitination and proteo-
somal degradation of p53 (4, 5). More recent evidence suggests
that MDM2 also functions as an ATP-dependent molecular
chaperone for p53 (6) and regulates the translation of p53 (7).
The complex interaction betweenMDM2 and p53 involves two
distinct binding sites on p53. By binding to the transactivation
domain of p53 (BOX-I) via itsN-terminal hydrophobic domain,
MDM2 disrupts the transcriptional activity of p53 (3, 8). This
interaction also results in conformational changes that facili-
tate binding between the S9-S10 linker/BOX-V region in the
core DNA binding domain of p53 and the acid domain of
MDM2 (9). The interaction with the acid domain is a lower
affinity interaction but importantly comprises the ubiquitina-
tion signal. Mutation of either the BOX-V region of p53 (9) or
the acid domain of MDM2 results in a decrease in the ubiquiti-
nation and degradation of p53 (9–11). Furthermore, ligands
that disrupt the p53-BOX-V:MDM2-acid domain interaction
are potent E3-ligase inhibitors in vitro and in cells (9). The dis-
covery of the role of the acid domain of MDM2 in ubiquitina-
tion of p53 has opened up new avenues for manipulating
MDM2 E3-ligase activity in cells.
MDM2 has multiple p53-independent functions that con-
tribute to its activity as an oncogene (12). The interferon regu-
latory factor (IRF)-2 transcription factor was recently identified
as a novel substrate for MDM2-mediated ubiquitination (13).
MDM2was found to bind to IRF-2 using a dual-sitemechanism
in a similar manner to p53, and acid domain interactions were
found to be crucial for MDM2-mediated ubiquitination, sug-
gesting a common mechanism for MDM2-catalyzed ubiquiti-
nation (13). Furthermore, the acid domain of MDM2 is impor-
tant in forming the interactionwith a number of other proteins,
including Arf (14), the retinoblastoma tumor suppressor pro-
tein (Rb) (15), and p21(Waf1) (16).
The cell fate determinantNUMBwas identified as anMDM2
binding partner using the N-terminal hydrophobic pocket
domain of MDM2 as bait in a yeast two-hybrid screen (17).
NUMB was subsequently shown to be ubiquitinated and
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degraded byMDM2 (18). NUMB is best known for its role as an
antagonist of the Notch signaling pathway (19, 20). NUMB
interacts with the active intracellular domain of Notch (NICD)
promoting degradation of Notch, preventing its localization to
the nucleus and its activity as a transcription factor (19, 20).
However, NUMB has also recently been shown to play a role in
the stabilization and activation of p53 in cells, whichwas shown
to be dependent on MDM2 (21). However, the exact mecha-
nism by which NUMB overcomes MDM2 inhibition of p53 is
still unclear. In this report, we investigate the interaction
betweenMDM2 andNUMB in detail and investigate the role of
the acid domain of MDM2 in the regulation of NUMB. In con-
trast to p53 where two separate domains form the interface
with MDM2, we demonstrate here that one region within the
phosphotyrosine binding (PTB) domain of NUMB interacts
with both theN terminus and the acid domain ofMDM2, high-
lighting the significance of the dual-site bindingmechanism. By
interacting with both these regions of MDM2, NUMB can dis-
rupt the p53-MDM2 complex and prevent ubiquitination of
p53. In addition, we show the importance of acidic domain
interactions for ubiquitination and degradation of NUMB.
Using peptides derived from the PTB domain of NUMB and
other small molecule ligands that bind to the acid domain of
MDM2, we can reverse the effects of MDM2 on degradation of
NUMB in cancer cells. Furthermore, these acid domain-bind-
ing ligands prevent MDM2-mediated ubiquitination resulting
in stabilization of p53 and the induction of growth arrest and
apoptosis in cells.
EXPERIMENTAL PROCEDURES
Antibodies, Plasmids, and Peptides—pCMV-His-ubiquitin,
pcDNA3.1-MDM2, and pT7.7/MDM2 were gifts from Prof.
David Lane. pcDNA3.1-NUMB and pGEX2T-NUMB were
gifts from Prof. M. Oren. Full-length NUMB, PTB domain, and
PTB domain of NUMB were subcloned into pFN2A and
pcDNA3.1vectors (Promega,Madison,WI) using the following
primers: pcDNA3.1-NUMB PTB forward (CCGGAATTCAT-
GCAGTGGCAGACAGATG) and reverse (CAACTCGACT-
TACCGCTTCTGCTTGCG), pcDNA3.1- NUMB PTB for-
ward (CCGGAATTCATGGAGAAGGAATGTGGAG) and
reverse (CAACTCGAGCGTTTAAAGTTCAATTTC), pFN2A-
NUMB forward (GTTCGCGATCGCCAACAAATTACGGC-
AAAGTTTTAG) and reverse (ACAGGTTTAAACAAGTTC-
AATTTCAAACGTCTTC), pFN2A-NUMB PTB forward
(CAAGCAGAAGCGGTGAGAGAAGGAATGTG) and re-
verse (CACATTCCTTCTCTCACCGCTTCTGCTTG), and
pFN2A-NUMBPTB forward (CACCGCGATCGCCGAGAA-
GGAATGTGGAGTGACTGC) and reverse (ATTAGTTTAAA-
CAAGTTCAATTTCAAACGTCTTCTGTAAGTCA). GST-
MDM2, GST-N MDM2, GST-AD MDM2, GST-AD
MDM2, and GST-N MDM2 have been previously described
(9). Goat anti-NUMB antibody (Abcam Ab 4147) was used to
detect NUMB. Anti-Notch 1, MAB5352 (Millipore), and anti-
Hes-1 (Santa Cruz Biotechnology, H140) were used to detect
NICD and Hes1, respectively. Monoclonal antibodies 4B2 and
2A10 were used to detectMDM2, and DO-1 antibody was used
to detect p53 (gifts from Prof. T. Hupp). Anti-GST and -actin
antibodies were from Sigma. p21 antibody (Ab1) was fromCal-
biochem. Biotin-labeled peptides were synthesized by Mimo-
topes (Australia). HIV-TAT Fluorescein-labeled peptides were
from Mimotopes (NUMB peptide 7 was VVDEKTDKDLIVD-
QTIEKVSFYGRKKRRQRRR, NUMB peptide 8 was KVSFCA-
PDRNFDRAFSYICRYGRKKRRQRRR, NUMB peptide 9 was
YICRDGTTRRWICHCFMAVKYGRKKRRQRRR, and Rb1
was DQIMMCSMYGICKVKNIDLKYGRKKRRQRRR).
Cell Culture and Immunoblots—H1299 and MD MB-468
were maintained in RPMI (Invitrogen) supplemented with 5%
FCS (Biosera) and 1% penicillin/streptomycin at 37 °C and 5%
CO2. MCF7, ZR75, and A375 were maintained in DMEM
(Invitrogen) supplemented with 5% FCS (Biosera) and 1% pen-
icillin/streptomycin at 37 °C and 5% CO2. The cells were trans-
fected at 80% confluency using Lipofectamine 2000 (Invitro-
gen) or Attractene (Qiagen) following the manufacturer’s
instructions, and DNAwas equalized by addition of empty vec-
tor control. Peptides were added to the cells as indicated in the
figure legends and incubated overnight. Cells were treated with
cisplatin (12 g/ml) for 24 h as indicated in the figures. Cells
were lysed, and immunoblots were carried out as previously
described (22).
Protein Purification—MDM2 was expressed and purified
from Escherichia coli (E. coli) as previously described (6). GST-
MDM2 and GST-NUMB constructs were expressed in E. coli
and purified on glutathione-Sepharose beads (GE Healthcare)
following the manufacturer’s instructions. The GST tag was
cleaved using Thrombin (Sigma), PreScission Protease (GE
Healthcare), or TEV Protease (Expedeon), following the man-
ufacturer’s instructions.
Ubiquitination Assays—Cell-based ubiquitination assays
were carried out in H1299 cells following transfection of
cells with pcDNA3.1-NUMB, pCMV-his ubiquitin, and
pcDNA3.1-MDM2 as previously described (9). The p53 ubiq-
uitination assays were carried out as previously described (9).
For NUMB the in vitro ubiquitination reactions contained 25
mM Hepes (pH 8.0), 10 mM MgCl2, 4 mM ATP, 0.5 mM DTT,
0.05% (v/v) Triton X-100, 0.25 mM benzamidine, 10 mM crea-
tine phosphate, 3.5 units/ml creatine kinase, ubiquitin (2 g),
E1-UBE-1 (100 nM), E2-UbcH5 (1M), andGST-NUMB (250–
500 ng). Reactions were started using purifiedMDM2 (50–100
ng), incubated for 3 h at 30 °C, and analyzed using 7% Tris
acetate NuPAGE gels in a Novex Tris acetate buffer system
(Invitrogen) followed by immunoblot with anti-NUMB anti-
body. Where peptides were used they were added to the reac-
tion mix prior to addition of MDM2 as indicated in the figure
legends.
ELISA Assays—For peptide ELISA, biotin-labeled peptides
were captured onto streptavidin-coated plates (25 g/ml,
Sigma) as detailed in the figure legends. Non-reactive sites were
blocked using PBS containing 3% BSA. The wells were incu-
batedwith full-lengthMDM2,mini-domainMDM2, ormutant
MDM2proteins (as indicated in the figure legends) in PBS-0.1%
BSA for 1 h at room temperature. The plates were washed
extensively with PBS-0.2% Tween, and MDM2 binding was
detected using anti-MDM2 antibodies: 2A10 or 4B2 or anti-
GST antibody and enhanced chemiluminescence (as indicated
in figure legends). For protein ELISA, 96-well microtiter plates
were coated with the protein (as detailed in the figure legends)
MDM2Dual-site Binding Regulates NUMB
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(MDM2 or MDM2 mutants (Fig. 1, B–E), NUMB or NUMB
mutants (Fig. 2G, p53; (Fig. 5,A and B)) in 0.1 M sodium borate.
Non-reactive sites were blocked using PBS containing 3% BSA,
and the wells were incubated with MDM2 (Figs. 2G and 5A),
NUMB (Fig. 1, B–E), in PBS, 0.1% BSA for 1 h at room temper-
ature. Bindingwas detected using the appropriate primary anti-
bodies and enhanced chemiluminescence as detailed in the fig-
ure legends. Competition ELISA assays were carried out as
above, but peptides were preincubated with MDM2 on ice for
30 min prior to adding to the plate. Readings were performed
using Victor3 1420Multilabel Counter (Perkin-Elmer) or Fluo-
roscan Ascent FL (Labsystems).
Colony Formation Assay—H1299 or A375 cells were trans-
fected at 90% confluency with pCDNA3.1-p53 (150 ng),
pCDNA3.1-MDM2 (250 ng), andDNAequalized by addition of
empty vector. Peptides were added to the cells 4 h post trans-
fection. After 24 h cells were then trypsin-treated and re-plated
at different concentrations into 10-cm dishes with RPMI or
DMEM containing 1.5 mg/ml Geneticin (Invitrogen). Media
was replaced after 3 days and then weekly with media plus
Geneticin. Colonies were counted after 15 days by fixing in
methanol for 30 min following staining with 10% v/v Giemsa
(Sigma).
Caspase-Glo 3/7 Assay—TheCaspase-Glo 3/7 assay was per-
formed using ZR75 and A375 cells at 80% confluency, in a
96-well format. Cells were transfected with plasmids or treated
with peptides for 18–24 h (as detailed in figure legend (Fig. 7,
D–H)) and then treated with cisplatin (12 g/ml) for a further
24 h where indicated in the figures. Cells were then processed
according to the Caspase-Glo 3/7 kit manufacturer’s protocol
(Promega).
FACS—MCF7cellswere seeded into a 6-well plate and grown
for at least 24 h prior to peptide treatment. Cells were incubated
with peptides (25 M) for 24 h as indicated. Cells were then
trypsinized and harvested by centrifugation and processed
according to theAnnexinVApoptosisDetectionKit APCman-
ufacturer’s protocol (eBioscience). Samples were analyzed at
the Flow Cytometry Facility, MRC Human Genetics Unit,
Western General Hospital, Edinburgh.
RESULTS
NUMB Binds to the Acidic Domain of MDM2—To under-
stand themechanismof action ofMDM2-mediated ubiquitina-
tion of NUMB and to determine how NUMB might inhibit
degradation of p53, we examined the interaction between
MDM2andNUMB indetail. Recent studies into the interaction
of the E3 ligase MDM2 with substrates such as p53 and the
transcription factor IRF-2 have demonstrated that MDM2
binds to its substrates using a dual-site mechanism (9, 13).
However, the salient interaction for p53 ubiquitination is bind-
ing of theMDM2acid domain to the coreDNAbinding domain
of p53, encompassing the BOXV/S9-S10 linker region (9, 23).
MDM2-mediated ubiquitination of IRF-2 also requires acid
domain interactions (13). NUMBwas previously shown to bind
to the N-terminal hydrophobic pocket of MDM2 (17, 18), but
we wanted to determine if, like p53 and IRF-2, the acidic
domain of MDM2 was also important in regulating the ubiq-
uitination and degradation of NUMB.
Our initial efforts sought to determine if NUMB could bind
to MDM2 orMDM2mini-domains in vitro using purified pro-
teins (Fig. 1A) in protein-protein interaction assays. Full-length
MDM2 or the N terminus of MDM2, purified from E. coli, was
immobilized on a plate, and binding to full-length NUMB was
detected using an anti-NUMB antibody (Fig. 1, B and C). As
expected, NUMB bound to both full-length MDM2 (Fig. 1B)
and the N terminus (Fig. 1C). The isolated acidic domain of
MDM2 (MDM2-AD) was then examined for NUMB binding
(Fig. 1D). Interestingly, NUMBdid form an interactionwith the
acidic domain of MDM2 (Fig. 1D). This result suggests that, in
a similar manner to p53, NUMB interacts with two distinct
regions of MDM2, the N-terminal hydrophobic pocket and the
acidic domain. When MDM2, missing the acidic domain,
MDM2-AD, (Fig. 1A) was then examined for NUMB binding
(Fig. 1E), we observed a dramatic reduction in binding to full-
length NUMB (Fig. 1E). This confirmed the significance of the
acidic domain as a major binding interface for NUMB.
The PTB Domain of NUMB Mediates Binding to MDM2—
Two separate regions on p53 are involved in dual-site binding
to MDM2. Therefore, to establish the regions of NUMB im-
portant in forming the interaction withMDM2, we synthesized
a panel of overlapping biotin-tagged peptides spanning full-
length NUMB and analyzed binding to MDM2 by a peptide-
protein interaction assay. The biotin-tagged peptides were
immobilized on a streptavidin-coated microtiter plate and
incubated with MDM2, and binding was detected by an anti-
MDM2 antibody. Two peptides within the PTB domain of
NUMB, peptides 8 and 9 (amino acids 113–148), were found to
interact withMDM2 (Fig. 2A). The PTB domain has previously
been shown to interact with the N terminus of MDM2 (17).
Therefore, we analyzed binding further to determine where the
PTB domain peptides bound on MDM2 using mini-domain
andmutant proteins (Fig. 1A). Peptide 9 ofNUMB (amino acids
129–148) could form an interaction with the N-terminal
hydrophobic pocket ofMDM2 (MDM2-N), similar to BOX-I of
p53 or BOX-I-like peptides such as 12.1 (24), which was used as
a positive control in this assay (Fig. 2B). Peptide 8 (amino acids
113–132) was unable to bind to this region (Fig. 2B). Although
peptide 9 bound theN-terminal hydrophobic pocket ofMDM2
when we used MDM2 missing the N terminus (MDM2-N)
(Fig. 2C), both peptide 8 or 9 could bind to this truncated form
of MDM2 (Fig. 2C), suggesting that regions other than the N
terminus of MDM2 also contribute to the interaction with the
PTB domain of NUMB.
The PTB domain peptides behaved more like the acidic
domain-binding peptide Rb1 than the hydrophobic pocket-
binding peptide BOX-1, and we have demonstrated above that
purified full-length NUMB could form an interaction with the
acid domain of MDM2 (Fig. 1D). Therefore, we wanted to
determine if the NUMB PTB domain peptides bound to the
acid domain. IndeedNUMBpeptides 8 and 9 bound strongly to
the acid domain ofMDM2 (MDM2-AD) (Fig. 2D). Nextmutant
MDM2, missing the acidic domain (MDM2-AD), was exam-
ined. In a similar manner to BOX-I of p53, peptide 9 was found
to bind toMDM2missing the acidic domain, but no significant
bindingwas observedwith peptide 8 (Fig. 2E). The above results
suggest that peptide 8 binds only to the acid domain and that
MDM2Dual-site Binding Regulates NUMB
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FIGURE 1.NUMBbinds to theAcidDomain ofMDM2.A, schematicdepicting full-length,mutant, andmini-domainMDM2 andNUMBproteins. ZF represents
the zinc finger domain of MDM2. MDM2-N is a mutant MDM2 missing the N-terminal hydrophobic pocket, which binds p53 BOX-I domain. MDM2 AD is
missing the acidic domain. NUMBPTB is missing the PTB domain of NUMB. B–E, 0–2g of purified MDM2-FL (B), MDM2-N (C), MDM2-AD (D), or MDM2-AD
(E) were bound to a 96-well microtiter plate and incubated with full-length NUMB, with the GST tag cleaved. Binding was detected with anti-NUMB antibody
followed by chemiluminescence with ECL reagent.
MDM2Dual-site Binding Regulates NUMB
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peptide 9 can interact with both the N terminus and acid
domain of MDM2. Although the N-terminal hydrophobic
pocket and acid domain are not directly adjacent to each other,
they may be close in the three-dimensional structure of the
protein allowing peptide 9 to bind into both regions
simultaneously.
MDM2Dual-site Binding Regulates NUMB
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FIGURE 2. PTB domain of NUMB binds to the N terminus and acidic domain ofMDM2. A, B, andD, biotin-tagged peptides to full-length NUMB (1–41) (3.5
M) captured on a streptavidin-coatedmicrotiter plate and incubatedwith purified full-lengthMDM2 (200 ng) (A), the isolatedN-terminal hydrophobic pocket
(MDM2-N) (200 ng) (B), or the isolated acid domain (MDM2-AD) (200 ng) (D) MDM2 binding detected with anti-MDM2 or anti-GST antibodies, followed by
chemiluminescence with ECL reagent. C and E, increasing concentrations of biotin-tagged peptides as indicated (0 to 70 M) were bound to a streptavidin-
coatedmicrotiter plate and incubatedwithMDM2missing theN terminus (MDM2-N) (200ng) (C) orMDM2missing the aciddomain (MDM2-AD) (200ng) (E).
MDM2 binding was detected with anti-GST antibody. F, upper panel: Full-length GST-NUMB protein (500 ng) captured onto a microtiter plate and incubated
with full-length MDM2 (200 ng), which had been preincubated with DMSO control or increasing concentrations of peptides as indicated (0 to 35 M). MDM2
binding was detected with anti-MDM2 antibody. The diagram to the left illustrates the experiment: when competing peptide bound to MDM2, then no
NUMB-MDM2 binding was detected. F, lower panel: Biotin-tagged NUMB peptides 8 and 9 (3.5 M) were bound to a streptavidin-coated plate followed by
incubation with MDM2 (200 ng), which had been preincubated with DMSO control or peptides as indicated (35 M). MDM2 binding was detected with
anti-MDM2 antibody. G, full-length NUMB (FL NUMB), the PTB domain of NUMB (PTB), NUMB missing the PTB domain ( PTB), or control GST-only and BSA
proteins were immobilized on a 96-well microtiter plate and incubatedwith either full-lengthMDM2 (upper graph) or the acidic domain of MDM2 (MDM2-AD)
(lower graph). Binding was detected with anti-MDM2 antibody followed by chemiluminescence with ECL reagent. H, the N terminus of MDM2 (MDM2-N) was
immobilized on a microtiter plate and incubated with full-length NUMB or NUMB missing the PTB domain ( PTB). Binding was detected with anti-NUMB
antibody followed by chemiluminescence with ECL reagent. The experiments shown in this figure represent at least three separate experiments.
FIGURE 2—continued
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Further confirmation of the importance of the acid domain
interaction was demonstrated by use of a protein-peptide com-
petition assay. Rb1 peptide, derived from the retinoblastoma
tumor suppressor protein, and BOX-V of p53 both bind to the
acid domain ofMDM2 (9). These peptides andNUMBpeptides
8 and 9 were preincubated with MDM2, and then binding to
NUMB was analyzed (Fig. 2F, upper panel). We found that,
when preincubated with MDM2, these acid domain-binding
ligands could inhibit the interaction of full-length NUMB with
MDM2. However, hydrophobic pocket-binding ligands BOX-I
andNutlin (25) could not (Fig. 2F, upper panel), confirming the
importance of acid domain interactions. Acid domain-binding
ligands, Rb1 and BOX-V, could also disrupt the interaction of
NUMB PTB domain peptides with MDM2 (Fig. 2F, lower
panel). Because BOX-I could not disrupt the interaction
between NUMB and MDM2, this result suggests that NUMB
may bind to a slightly different region in the N terminus of
MDM2 than p53.
To analyze these results further we made truncated NUMB
proteins that were terminated after the PTB domain or missing
the PTB domain (Fig. 1A). These proteins were then tested for
binding to full-length MDM2 and to the isolated N-terminal
and acidic domains of MDM2 by protein-protein interaction
assays. The isolatedPTBdomain ofNUMBbound to full-length
MDM2and the acidic domain (Fig. 2G), although a reduction in
binding was observed compared with the full-length protein.
When the truncated NUMB protein missing the PTB domain
was examined, there was a dramatic reduction in binding to the
acidic domain and also to full-lengthMDM2 (Fig. 2G).We then
examined binding to the N terminus of MDM2 but did not see
any binding to the PTB domain in this assay (data not shown).
However, this may be due to the fact that the binding site was
maskedwhen the PTBdomainwas bound to the plate, as others
have previously shown that the N terminus of MDM2 inter-
acted with the PTB domain of NUMB (17). However, a dra-
matic reduction in binding to the N terminus of MDM2 was
observed with the truncated form of NUMB, missing the PTB
domain (Fig. 2H), suggesting that this is also an important bind-
ing region for the N terminus of MDM2.
Investigation into the Critical Residues of NUMB PTB
Domain Involved in MDM2 Binding—Our results imply that
the PTB domain peptides bind to both the N terminus and
acidic domains ofMDM2. Therefore, to determine the residues
in peptides 8 and 9 that were important in forming the interac-
tionwithMDM2,we carried out an alanine scan of the peptides,
where each residue in turn was mutated to alanine (any alanine
residues in the wild-type peptide were mutated to glycine), and
then binding toMDM2was assessed by a peptide-protein inter-
action assay (Fig. 3A).We observed that a number of residues in
peptides 8 and 9 whenmutated to alanine had reduced binding
to MDM2 (highlighted in red, Fig. 3A). Because peptide 9 of
NUMB appeared to bind to both the hydrophobic pocket and
the acidic domain of MDM2, we analyzed the alanine scan of
peptide 9 further to determine what residues were important
for binding to each region of MDM2 by using the isolated N
terminus or acidic domain proteins (Fig. 1A). Mutation of res-
idues isoleucine 130, arginine 132, tryptophan 139, and lysine
148 of NUMB showed greatest reduction in binding to the
acidic domain (MDM2-AD) compared with wild-type peptide
9; therefore, we propose that these residues are important for
mediating binding to the acidic domain of MDM2 (Fig. 3B).
Whenwe compared the sequence of the NUMBpeptides to the
Rb1 peptide (amino acids 701–720 of Rb), which binds to the
acidic domain of MDM2, we identified an area of homology
between Rb and NUMB at the end of peptide 8 and start of
peptide 9, where the peptides overlap: YGICK (amino acids
708–712) in Rb and Y-ICR (amino acids 129–132) in NUMB
(Fig. 3C). This correlates with our results demonstrating that
these residues were important forMDM2binding (Fig. 3,A and
B). On the other hand, mutated amino acids 140–143 demon-
strated slightly reduced binding to theN-terminal hydrophobic
pocket compared with wild-type peptide 9 (Fig. 3D). Because
peptide 9 binds very strongly to the N-terminal region, we
titrated the peptide 9mutant peptides further and saw a greater
reduction in binding to the N-terminal hydrophobic pocket of
MDM2, compared with wild-type peptide (Fig. 3E, upper
graph). The peptide with amutated histidine, H142A, in partic-
ular showed the greatest reduction in binding. However, the
residues important for acidic domain binding above were not
significantly reduced compared with the wild-type peptide 9
(Fig. 3E, lower graph). These results demonstrate that, although
the PTB domain interacts with two domains onMDM2, differ-
ent residues within the PTB domain form the interface with the
N terminus and the acidic domain of MDM2.
Contribution of MDM2 Domains to MDM2-mediated Ubiq-
uitination of NUMB—Because the acidic domain is important
for catalyzing ubiquitination of otherMDM2 substrates (9, 13),
we wanted to determine the significance of the acidic domain
for NUMB ubiquitination. Initially, we confirmed MDM2-me-
diated ubiquitination of NUMB using a well characterized in
vivo ubiquitination assay (26). NUMBwas transfected into cells
in the presence ofMDM2 andHis-tagged ubiquitin, and a pull-
down assay on nickel beads followed by immunoblot analysis
was carried out. NUMB was efficiently ubiquitinated in the
presence of MDM2 but not in its absence (Fig. 4A). These
results confirm earlier reports demonstrating that NUMB is
ubiquitinated by MDM2 (18). An in vitro ubiquitination assay
was then set up that employed purified components. NUMB,
purified fromE. coli, was not ubiquitinated in the absence of E1,
E2, or MDM2 (Fig. 4B, lanes 1, 3, and 4). However, in the pres-
ence of E1, E2, and full-lengthMDM2, NUMBwas subjected to
modification producing a characteristic ubiquitin ladder in
vitro (Fig. 4B, lane 2).
Having confirmed thatNUMB is ubiquitinated byMDM2we
then determined the contribution of different MDM2 domains
to the ubiquitination of NUMB. When MDM2, missing the
acidic domain, MDM2-AD (Fig. 4C, upper panel, lanes 4–6),
was examined, no ubiquitination was observed compared with
wt MDM2 (Fig. 4C, upper panel, lanes 1–3), although mutant
MDM2 proteins were present in similar quantities to wild-type
protein in the assay (Fig. 4C, lower panel). MDM2, missing the
N-terminal domain,MDM2-N (Fig. 1A), also appeared to lose
the ability to catalyze ubiquitination of NUMB using low
amounts of MDM2 in the assay (Fig. 4C, upper panel, lane 7).
However, whenhigher amounts ofMDM2-Nwere used in the
reaction, the distinct mono-ubiquitination ladder observed
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with the wild-type MDM2 was visible but reduced compared
with wt MDM2. However, NUMB appeared to be poly-ubiq-
uitinated, and less un-ubiquitinated NUMB appeared to be
present (Fig. 4C, upper panel, lanes 8 and 9). The changes to
ubiquitination of NUMB may be due to a conformational
change in the MDM2 protein as a result of the loss of the N
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terminus. However, the results demonstrate that the acid
domain of MDM2 is crucial for ubiquitination of NUMB.
Acid Domain-binding Ligands Inhibit MDM2-mediated
Ubiquitination of NUMB—We have shown above that acid
domain-binding ligands can inhibit the NUMB-MDM2 inter-
action. Next, we wanted to determine the potential of the acid
domain-binding ligands as inhibitors of MDM2-mediated
ubiquitination of NUMB. Interestingly, all the acid domain-
binding ligands, Rb 1, BOX-V, and peptides 8 and 9 from
NUMB, could inhibit MDM2-mediated ubiquitination of
NUMB in vitro (Fig. 4D). We have previously demonstrated
that hydrophobic pocket-binding ligands like BOX-I and Nut-
lin are unable to inhibitMDM2-catalyzed ubiquitination of p53
(9) or IRF-2 (13). In a similar manner to p53, ubiquitination of
NUMB was not inhibited by BOX-I or Nutlin in this assay (Fig.
4D), which also correlates with earlier results suggesting these
N-terminal MDM2-binding peptides do not disrupt the inter-
action between NUMB and MDM2 (Fig. 2F). Peptide 7 of
NUMB was used as a control in this assay, because it did not
bind toMDM2 (Fig. 2A), and indeed it did not inhibit ubiquiti-
nation (Fig. 4D).
NUMB PTB Domain Peptides Disrupt the MDM2-p53 Inter-
action andMDM2-mediated Ubiquitination of p53—NUMB is
found in a trimeric complex withMDM2 and p53 and has been
FIGURE 3. Determination of the critical residues in NUMB that mediate binding to MDM2. A, biotin-tagged NUMB peptides 8 and 9 wild-type (WT) or
mutant peptide (7M) as indicated were captured onto a streptavidin-coatedmicrotiter plate and incubated with full-lengthMDM2 (200 ng). MDM2 binding
was detected with an anti-MDM2 antibody. The residue that was changed to alanine is shown below the graph, and critical residues for MDM2 binding are
highlighted in red. B and D, alanine scan of peptides of biotin-tagged peptide 9 (3.5 M) bound to a microtiter plate and incubated with GST-tagged MDM2
acidic domain (MDM2-AD) (B) or N terminus (MDM2-N) (D). MDM2 binding was detected with anti-GST antibody. Critical residues for MDM2 binding are
highlighted in red. C, alignment of MDM2 binding regions of NUMB, Rb, and BOX-I of p53. Homologous residues are indicated in red, residues similar to BOX-I
are in bold. E, upper and lower panel: Increasing amounts of biotin-tagged alanine scan of peptide 9 (0 to 70 M as indicated) were bound to a streptavidin-
coated plate and incubated with the GST-tagged MDM2 N terminus (MDM2-N). Peptide-bound MDM2 was detected with an anti-GST antibody.
FIGURE 4. Contribution of MDM2 domains to the ubiquitination of NUMB. A, H1299 cells transfected with Numb (7.5 g) in the presence and absence of
His-Ubiquitin (10 g) and Mdm2 (5 g) as indicated. Samples were supplemented with empty vector, so that the final concentration of DNA was the same in
all reactions. Cells were treated for 6 h with 25 M MG132 before harvesting. 10% of the cell suspension was analyzed for total protein levels. The His-tagged
ubiquitinated proteins were isolated using Ni-NTA-agarose (Qiagen) 48 h post transfection and analyzed by immunoblotting on a 7% Tris-acetate gel (Invit-
rogen)with anti-NUMB antibody. B, NUMB (250 ng)was incubated in the presence of ubiquitin (2M) and in the presence or absence of E1 (UBE-1) (100 nM), E2
(UbcH5) (1 M), and MDM2 (100 ng) as indicated. Ubiquitination was detected by Western blotting with anti-NUMB antibody, where Ub-NUMB represents
ubiquitinated NUMB. C, upper panel: NUMB (250 ng) was incubated in the presence of ubiquitin (2 M), E1 (UBE-1) (100 nM), E2 (UbcH5) (1 M), and increasing
amounts of wild-type MDM2 (lanes 1–3) or MDM2 missing the acidic domain (MDM2-AD) (lanes 4–6) or missing the N terminus (MDM2-N) (lanes 7–9)
(100–500 ng). Ubiquitination was detected by Western blotting with anti-NUMB antibody, where Ub-NUMB represents ubiquitinated NUMB. Lower panel:
GST-tagged MDM2 wt, AD, and N protein (same amounts as those used for ubiquitination assay) run out on SDS-PAGE and stained with Coomassie Blue
reagent. D, NUMB (250 ng) was incubated with ubiquitin (2 M), E1 (100 nM), and E2 (1 M) and in the presence or absence of MDM2 (100 ng) and varying
amounts of ligand (10, 20, and 40 M) or DMSO control as indicated. Samples were analyzed by SDS-PAGE and immunoblotting with anti-NUMB antibody,
where Ub-NUMB represents ubiquitinated NUMB. Experiments presented in this figure are representative of at least three separate experiments.
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shown to play a role in the stabilization of p53 in cells (21).
However, the mechanism by which NUMB prevents the degra-
dation of p53 is still unclear. Because we found that NUMB
binds to the same regions onMDM2 as p53, namely, the N-ter-
minal hydrophobic pocket and the acidic domain, we hypothe-
sized that NUMB could interfere with theMDM2-p53 interac-
tion and thereby disrupt MDM2-mediated ubiquitination.
Initiallywe sought to determine if theNUMB full-length pro-
tein would disrupt the p53-MDM2 complex. We observed
binding of purified full-length p53 to MDM2 in a protein-pro-
tein interaction assay, however, in the presence of NUMB,
MDM2 binding was severely reduced (Fig. 5A). In addition,
NUMB protein could also disrupt the interaction of MDM2
with both BOX-I and BOX-V regions of p53 (Fig. 5A). The
NUMB PTB domain-derived peptides 8 and 9 were then
examined in this assay, and we observed that they could dis-
rupt p53 binding to MDM2 better than the other acid
domain-binding peptide Rb1 and even better than Nutlin
(Fig. 5B). NUMB was previously shown to bind to p53 in an
immunoprecipitation assay in the absence of MDM2, sug-
gesting a direct interaction between NUMB and p53 (21).
However, we did not detect p53 binding to any of the NUMB
peptides (data not shown).
Because other acid domain-binding ligands, such as Rb1, dis-
rupt theMDM2-p53 complex and also inhibit ubiquitination of
p53, the NUMB PTB domain peptides were tested in this assay.
Similar to Rb1, both peptides 8 and 9 of NUMBwere found to
strongly inhibit MDM2-mediated ubiquitination of p53 in
vitro (Fig. 5C). The control peptide 7 was unable to inhibit
ubiquitination of p53 (Fig. 5C). The results presented sug-
gest that, by binding to similar regions on MDM2 as p53,
NUMB can disrupt the MDM2-p53 complex and inhibit
ubiquitination of p53.
Acid Domain-binding Ligands Promote Stabilization of
NUMBand p53 in Cells—NUMBhas previously been shown to
be frequently ubiquitinated and degraded in breast cancer cells
(27). We and other groups have previously shown that a small
peptide could mimic a full-length protein and inhibit MDM2
function (9, 28, 29). Our results above suggest that, by using
specific acid-domain-binding inhibitors of MDM2, we may be
able to restore NUMB in breast cancer cells and also stabilize
p53. Initially we examined a panel of breast cancer cells to
determineMDM2 and NUMB protein expression levels. Inter-
estingly we observed an inverse correlation between NUMB
and MDM2 (Fig. 6A). Overexpression of MDM2 in osteosar-
coma cells has previously been shown to result in degradation
of NUMB (17). In addition, we demonstrate that overexpres-
sion of MDM2 in MDA MB 468 and ZR75 breast cancer cells
resulted in degradation of NUMB (Fig. 6B).
The basic domain of HIV-TAT-(49–57) (RKKRRQRRR) has
been well used recently as a tool to deliver proteins/small mol-
ecule peptides to cells and tissues (30–32). Therefore, the acid
domain-binding peptides were synthesized fused to HIV-TAT
and with a fluorescent label for intracellular delivery. Fluores-
cence microscopy was used to determine cellular localization
(Fig. 6C). All peptides examined were found to localize to the
nucleus and cytoplasm (Fig. 6C), although not all cells exam-
ined display bright fluorescent staining.
FIGURE 5. Acid domain-binding ligands inhibit MDM2-mediated ubiq-
uitinationofp53bydisrupting theMDM2-p53complex.A, full-lengthp53
protein (50 ng) or p53 peptides (BOX-I or BOX-V, 3.5 M) were captured onto
a microtiter plate and incubated with full-length MDM2 (200 ng), which had
beenpreincubatedwith increasingconcentrationsofNUMBas indicated (0 to
200 ng). BoundMDM2was detected with anti-MDM2 antibody. B, full-length
p53 protein (50 ng) captured onto a microtiter plate and incubated with full-
lengthMDM2 (200 ng), which had been preincubated with DMSO or increas-
ing concentrations of peptides as indicated (0 to 35 M). Bound MDM2 was
detected with anti-MDM2 antibody. The diagram to the left illustrates the
experiment: when competing peptide binds MDM2, then no p53-MDM2
bindingwas detected. C, full-length p53 protein (50 ng) incubatedwith ubiq-
uitin (2 M), E1 (100 nM), and E2 (1 M) in the presence or absence of MDM2
(100 ng) and increasing amounts of peptides (10, 20, and 40 M) or DMSO.
Samples were analyzed by immunoblotting with anti-p53 antibody, where
Ub-p53 represents ubiquitinated p53.
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To examine the effects of the peptides we used MCF7 breast
cancer cells, which have wild-type p53 and express high levels
of MDM2 and lower levels of NUMB (Fig. 6A). Upon addition
of acid domain-binding ligands toMCF7 breast cancer cells, we
observed an increase in NUMB protein levels, particularly
when 50 M of the NUMB PTB domain-derived peptides were
added (Fig. 6D), although Rb1 peptide was just as good an
inhibitor at 20 M. Furthermore, after addition of the acid
domain-binding ligands to cells, expression of both the
active intracellular domain of Notch1 (NICD) and its down-
stream target Hes1 were reduced compared with untreated
or control peptide 7-treated cells (Fig. 6D), demonstrating an
effect of the stabilization of NUMB on its downstream tar-
gets in these cells.
The acid domain-binding ligands were then examined further
to determine if they could stabilize p53 in cells. Indeed, 24 h after
addition of the peptides toMCF7 breast cancer cells, we observed
an increase in protein expression levels of p53 (Fig. 6E), which
correlated with the enhancement of NUMB in the presence of
these inhibitors that we showed earlier (Fig. 6D). Furthermore,
elevated levels of p21, a downstream target of p53, were also
observed (Fig. 6E). Along with the stabilization of p53 observed,
ubiquitination of p53 was also inhibited in cells after addition of
the NUMB PTB domain peptides (Fig. 6F).
FIGURE 6.MDM2 acid domain-binding ligands stabilize NUMB and p53 in breast cancer cells. A, panel of breast cancer cells (MCF7, MDA MB 468, ZR75,
SKBR, T47D, and BT 474) and a lung cancer cell line, H1299 (used as a control for highNUMB and lowMDM2expression) immunoblotted for protein expression
levels of NUMB,MDM2, and-actin loading control as indicated. B, left panel: MDA-MB468 cells transiently transfectedwithMDM2or empty vector control (ev)
(2 g) as indicated for 24 h followed by immunoblotting with anti-MDM2, anti-NUMB, and -actin as indicated. Right panel: ZR75 cells were transiently
transfected with increasing amounts of MDM2 (0.25, 0.5, 1, and 2 g). DNA was equalized by addition of empty vector (ev). Samples were analyzed by
immunoblottingwith anti-MDM2, anti-NUMB antibodies, and -actin as indicated. C, HIV-TAT-fused peptides 8 and 9 and Rb1were added toMCF7 cells at 20
M and analyzed using the FITC and bright-field channels with the Zeiss AxioVision System. Vectashield media with DAPI (Vector) was used to visualize the
nuclei. D: Left panel, MCF7 cells treated with 20 or 50 M of peptides for 24 h as indicated. Cells were analyzed by immunoblotting with antibodies to NUMB,
NICD, Hes1, and-actin loading control as indicated. Right panel, Densitometry of the immunoblots shown on the left. E: Left panel, MCF7 cells treatedwith 20
and 50 M of peptides for 24 h as indicated. Cells were analyzed by immunoblotting with antibodies to p53, p21, and -actin as indicated. Right panel:
Densitometry of the immunoblots shown on the right. The experiments presented in this figure are representative of at least three separate experiments.
F, H1299 cells transfected with His-ubiquitin (1 g) and p53 (150 ng) in the presence of MDM2 (1 g) and HIV-TAT-fused peptides (10, 20, and 50 M) as
indicated. Ubiquitinated p53 was isolated 2 h after treatment withMG132 (20M) and 24 h post transfection and analyzed by immunoblotting with anti-p53,
where Ub-p53 represents ubiquitinated p53.
MDM2Dual-site Binding Regulates NUMB
14062 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 17•APRIL 20, 2012
 by guest on M
ay 2, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
MDM2Dual-site Binding Regulates NUMB
APRIL 20, 2012•VOLUME 287•NUMBER 17 JOURNAL OF BIOLOGICAL CHEMISTRY 14063
 by guest on M
ay 2, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Acid Domain-binding Ligands Induce Growth Suppression in
Cells—The above results demonstrate that the NUMB PTB
domain peptides and other acid domain-binding ligands can
increase the stability of p53 in cells and predicts that p53-me-
diated responses, such as growth suppression and apoptosis,
would also be enhanced. Therefore, to test the effect of the acid
FIGURE 7—continued
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domain-binding peptides on growth suppression, we set up a
colony formation assay in p53-null H1299 cells (Fig. 7A). As
expected, when p53 was overexpressed in these cells fewer col-
onies were observed compared with empty vector control.
When low levels of MDM2 were co-transfected with p53, it
could overcome the p53-induced suppression of growth.All the
acid domain-binding peptideswere able to reverse the effects of
MDM2 in this assay and restore the p53-induced suppression
of growth (Fig. 7A). Peptide 7 of NUMB, which does not bind to
MDM2, was used as a control and was unable to overcome the
effects ofMDM2.This suppression of growthwas also observed
in the A375, melanoma cell line (Fig. 7A). The effect of the
peptides was due to p53, because no effect on growth was
observed in the absence of transfected p53 in the p53-null
H1299 cells, but some growth arrest was observed, especially
with the Rb1 peptide, in A375 cells containing wt p53 (Fig. 7A).
Acid Domain-binding Ligands Induce Apoptosis in Cells—
Considering the results of these experiments, we wanted to
investigate the effect of the peptides on the induction of apo-
ptosis. Initially, the effect of the acid domain-binding ligands
was examined by FACS analysis using Annexin V staining (Fig.
7B). MCF7 breast cancer cells were examined at different time
points after addition of the peptides (data not shown), and we
found the most dramatic effects were observed at 24 h and;
therefore, this time point was used for all further experiments.
After addition of NUMB peptide 9 to the cells, we observed a
dramatic increase in the percentage of early apoptotic cells,
compared with the control peptide 7. The number of late apo-
ptotic cells was also increased compared with controls in the
presence of NUMB peptide 9 (Fig. 7B). NUMB peptide 8 and
Rb1 peptide were then examined for induction of apoptosis in
MCF7 cells (Fig. 7C). A very slight increase in early apoptosis
was observed with NUMB peptide 8, but a more dramatic
induction of late apoptosis was observed with this peptide.
Addition of Rb1 resulted in an increase in the percentage of
both early and late apoptotic cells (Fig. 7C).
In addition to annexin V, activation of caspase3/7 was also
examined in ZR75 cells (Fig. 7D). After addition of the Rb1
peptide, an increase in caspase activationwas observed (Fig. 7D,
upper panel), but the negative control peptide 7 was unable to
activate the caspases. TheNUMBPTBdomain peptides 8 and 9
were then examined in this assay to determine if they could
induce apoptosis. Peptides 8 and 9 enhanced activation of
caspase3/7 in the cells, compared with the control without any
peptide (Fig. 7D, lower panel).
This effect was not cell-type-specific or breast cancer-spe-
cific, because the peptides also could activate caspases 3/7 in
A375 cells (Fig. 7E, upper panel). However, no effect was
observed with the peptides in p53-null H1299 cells (data not
shown), indicating p53 dependence. The activation of caspases
3/7 correlated with an increase in the stabilization of p53
observed after treatment of A375 cells with the acid domain-
binding ligands (Fig. 7E, lower panel).
The PTBDomain of NUMBEnhances p53-induced Apoptosis
in Response to DNADamage—NUMBwas previously shown to
enhance stabilization of p53 after DNA damage, resulting in
FIGURE 7.Acid domain-binding ligands overcomeMDM2 inhibition of p53. A, table depicting colony formation assays carried out in H1299 and A375 cells
transfected with p53 (150 ng) and MDM2 (250 ng) and compared with empty vector control as indicated. Increasing amounts of peptides (5, 10, and 20 M)
were added toH1299 cells and 20Mof peptides to A375 cells 4 h post transfection as indicated. After 24 h, cells were then trypsin-treated and re-plated. After
15 days colonies were fixed, stained with Giemsa (Sigma), and counted. Nt indicates not treated. The photographic results with one of the peptides Rb1, in
H1299cells is shownbelow.BandC,MCF7cells treated induplicatewith25Mpeptides for 24has indicated. Cellswere trypsinizedandAnnexinV-stainedwith
Allophycocyanin (APC)-tagged antibody. Flow cytometry was performed after the addition of DAPI. Results are also presented graphically as percentage of
apoptotic cells. D, ZR75 cells treated with peptides at 2.5, 5, and 10M as indicated. Caspase activation was analyzed after 18-h incubation with the peptides.
E: Upper panel: A375 cells left untreated or treated with 10 or 20 M peptides as indicated. Caspase activation was analyzed after 18-h incubation with the
peptides. Lower panel: A375 cells were left untreated (ut) or treatedwith peptides (20M) as indicated for 18 h and then analyzed by immunoblottingwith p53
and -actin antibodies. Densitometry of the immunoblots is shown on the right. F: Upper panel, A375 cells left untreated or treated with 10 or 20M peptides
for 18 h as indicated. Cells were then left untreated as a control or treated with cisplatin (12 g/ml) for 0 or 24 h as indicated. Caspase activation was then
analyzed. Lower panel, A375 cells were left untreated (ut) or treatedwith peptides as indicated for 18 h followed by treatment with or without cisplatin (12g)
for 24 h as indicated. Cells were collected and analyzed for levels of p53 and -actin by Western blotting. Densitometry of the immunoblots is shown on the
right.G, A375 cellswereuntransfected (nt) or transfectedwith400ngof either empty vector (EV), full-lengthNUMB (NUMBFL), truncatedNUMBmissing thePTB
domain (NUMB PTB), or the isolated PTB domain of NUMB (NUMB PTB) as indicated. Caspase activation was analyzed 24 h post transfection. H: Upper panel,
A375 cells were transfected as inG, but cells were then left untreated or treatedwith cisplatin (12g/ml) for 24 h, as indicated, followed by analysis for caspase
activation. Lower panel, A375 cells treated as above in G and H, but cells were collected and analyzed for levels of p53 and -actin by Western blotting as
indicated. Densitometry of the immunoblots is shown on the right. The experiments presented in this figure are representative of at least three separate
experiments.
FIGURE 7—continued
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enhancement of p53-dependent apoptosis (21). Therefore,
activation of caspases 3/7 was examined in A375 cells following
treatment with cisplatin. Compared with untreated cells, cis-
platin resulted in activation of the caspases, which was further
enhanced by addition of the acid domain-binding peptides to
the cells (Fig. 7F, upper panel). Nutlin was used as a positive
control and Numb peptide 7 as a negative control in these
experiments. In addition, we observed stabilization of p53 lev-
els after treatment of the A375 cells with cisplatin, which was
enhanced by the acid domain-binding ligands (Fig. 7F, lower
panel).
To determine the significance of the PTB domain in stabili-
zation of p53 and activation of apoptosis further, we transfected
A375 cells with full-length NUMB, compared with NUMB
missing the PTB domain (NUMBPTB) or NUMB truncated
after the PTB domain (NUMB PTB) in this assay. Full-length
NUMB and the PTB domain (NUMB PTB) on its own were
capable of stimulating caspase activation (Fig. 7G). However, a
reduction in caspase activationwas observedwithNUMBmiss-
ing the PTB domain (NUMB PTB) (Fig. 7G). In addition,
unlike the mutant NUMB missing the PTB domain, NUMB or
the isolated PTB domain of NUMB could enhance caspase acti-
vation after cisplatin treatment of A375 cells (Fig. 7H, upper
panel). Correlating with these results, p53 was stabilized in the
presence of transfected full-length NUMB or slightly by the
PTB domain of NUMB but not in the absence of the PTB
domain (Fig. 7H, lower panel). These results suggest the impor-
tance of the PTB domain in mediating the effect of NUMB on
the p53 response to DNA damage.
Wehave highlighted in this report the importance of the PTB
domain of NUMB and the MDM2 dual site-binding mecha-
nism for MDM2-mediated regulation of NUMB. The signifi-
cance of the PTB domain ofNUMB in the regulation of p53was
also demonstrated. By targeting the acid domain of MDM2
with small molecule peptide inhibitors, we can enhance levels
ofNUMBand restore the levels and tumor suppressor activities
of p53 in cells, which identifies the acid domain as a potential
target for drug discovery.
DISCUSSION
MDM2 uses a dual-site mechanism to ubiquitinate and
degrade substrates such as p53 and IRF-2, involving acidic
domain interactions (9, 13). Previous reports from others using
mutational analysis have also demonstrated the significance of
the acidic domain ofMDM2 for its E3 ligase activity (10, 11). In
this report we now demonstrate that MDM2 uses this same
dual-site mechanism, involving N-terminal hydrophobic
pocket and acidic domain interactions, to regulate levels of the
cell fate determinant NUMB, another physiological relevant
target of MDM2. However, in contrast to p53, which binds to
MDM2 through two separate domains, the BOX-I transactiva-
tion domain and the BOX-V S9-S10 linker region in the core
DNAbinding domain,NUMBmediates binding to the two sites
inMDM2 throughone regionwithin the PTBdomain. ThePTB
domain of NUMB is known to be critical for NUMB function in
vivo, and overexpression of rat NUMB PTB domain alone
affected neural development (33).
The N terminus of MDM2 was previously shown to interact
with the PTB domain of NUMB (17). Our results demonstrate
that two 20-residue peptides within the PTB domain of NUMB
are able to bind to MDM2. We have narrowed down the inter-
action between the PTB domain and MDM2 to amino acids
113–148 of NUMB with amino acids 140–143 contributing to
the interaction with the N-terminal hydrophobic pocket. Dif-
ferent residues within the PTB domain were involved in acidic
domain binding. Although these regions of MDM2 are not
adjacent in the protein they may lie beside one another in the
three-dimensional conformation of the protein, allowing
NUMB to bind simultaneously to both domains. It is not
unusual for a short peptide sequence to accommodate binding
to more than one region or to more than one protein. The C
terminus of p21 contains overlapping recognition sites for both
cyclins and proliferating cell nuclear antigen, and a 20-mer pep-
tide is sufficient to mimic the assembly role of full-length p21
(34). The structure of the NUMB PTB domain is similar to
other PTB domain- containing proteins such as Shc, X11, and
IRS-1 (35) and appears to have a broad binding specificity, capa-
ble of binding to multiple peptides that share no strong
sequence similarity (35–37). These diverse sequences appear to
bind at a common binding site within a large hydrophobic sur-
face groove in the PTB domain. Our results demonstrate that
some of the residues exposed in the peptide-binding groove of
the NUMB-PTB domain are involved in binding to MDM2.
Residues Lys-148, Ala-151, and Arg-165 of dNUMB (Lys-113,
Ala-118, and Arg-132 in hNUMB) have all been shown to be
involved in binding to theNak peptide (38), and we found these
residues were also important for MDM2 acidic domain
binding.
Deletion of the acidic domain resulted in loss of binding to
NUMB and loss of MDM2-mediated ubiquitination. These
results correlatewith our previous findings, demonstrating that
acidic domain interactions are critical for MDM2-mediated
ubiquitination of p53 and IRF-2 (9, 13). Interestingly, NUMB is
thought to play a role in the stabilization of p53 in cells (21, 39),
although themechanismNUMBuses to achieve stabilization of
p53 was unclear. We demonstrate here the mechanism
wherebyNUMB stabilizes p53 in cells. By binding to both theN
terminus and the acidic domain of MDM2 PTB domain-de-
rived peptides could physically disrupt the p53-MDM2 com-
plex and inhibit ubiquitination of p53. No real homology was
found between PTB domain peptides andMDM2 hydrophobic
pocket-binding ligands, such as BOX-I of p53. Also, the BOX-1
peptide or Nutlin could not disrupt the interaction between
NUMB andMDM2 or MDM2-mediated ubiquitination. How-
ever, MDM2 includes a sequence in the N-terminal hydropho-
bic pocket (YLGQYI), which resembles the YIGPYF motif.
Mutations at Gly-58 of MDM2 (G in above motif) resulted in a
decrease in the association ofMDM2with both p53 andNUMB
(17), and full-length NUMB could disrupt the BOX-I-MDM2
complex, suggesting there may be some overlap in binding
regions. In addition, deletion of the PTB domain resulted in a
dramatic decrease in binding to the N terminus and the acidic
domains of MDM2.
MDM2 is tightly regulated in the cell, which involves a num-
ber of mechanisms, including protein-protein interactions,
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protein turnover by ubiquitination, and post-translational
modification, such as phosphorylation on multiple sites. Both
the N terminus and the acidic domain of MDM2 contain resi-
dues that are targeted by a number of kinases that phosphory-
late MDM2, resulting in changes in the stabilization of p53 (40,
41). This may also be the case for MDM2-mediated regulation
of NUMB. CKI phosphorylates the acidic domain of MDM2,
and this appears to play two distinct roles in regulating p53.
Small molecule inhibitors of CK1 or siRNA to CK1 can sta-
bilize p53 in cells (41). When CK1 was knocked out in cells a
change in the stabilization of p53was observed, althoughwedid
not observe any change in stabilization of NUMB in CK1
knock-out cells.3 This indicates that CK1a integration into
MDM2 is specific to p53 and does not integrate with NUMB.
However, it is highly likely that other kinasesmay be involved in
regulating the interaction withMDM2 and the levels of NUMB
in cells, whichmay impact on the tumor suppressor activities of
p53.
The results in this report and our previous studies (9) on the
discovery of the acid domain-binding ligands as potential inhib-
itors of MDM2-mediated ubiquitination lead us to design tools
to investigate these interactions further in cells and to deter-
mine their effect on the tumor suppressor activities of p53.
Using the peptides fused to HIV-TAT, we could deliver them
into the cell and demonstrate that the acid domain-binding
ligands could enhance levels of NUMB in breast cancer cells. In
a similar manner to other acid domain-binding peptides (9), we
demonstrated that a small fragment from the NUMB PTB
domain could not only disrupt the interaction between p53 and
MDM2but could also inhibit ubiquitination and degradation of
p53 in cells. Further analysis of the acid domain-binding ligands
revealed that, by targeting the acidic domain of MDM2, the
function of p53 as a tumor suppressor protein could be restored
in cells with all the acid domain-binding ligands inducing a
growth arrest and apoptosis in cells.NUMBhas previously been
shown to enhance the p53-mediated response to apoptosis
after DNAdamage (21). Indeed, in this report we demonstrated
that the acid domain-binding ligands could enhance apoptosis
after treatment of the cells with cisplatin and we also demon-
strated the significance of the PTB domain of NUMB for this
enhancement of p53-mediated apoptosis.
NUMB is also a major regulator of the Notch signaling path-
way, and aberrant activation of Notch is frequently found in
breast cancer as a result of ubiquitination and degradation of
NUMB.We observedMDM2-mediated degradation of NUMB
in breast cancer cells, and it is likely thatMDM2may contribute
to the degradation of NUMB and activation of Notch in breast
cancer. Therefore, the MDM2-NUMB complex may regulate
both the p53 and Notch pathways. This also highlights the
importance of targeting the acidic domain of MDM2 for drug
discovery. Indeed, treatment of MCF7 cells with the acid
domain-binding ligands demonstrated a reduction in the acti-
vated form of Notch, NICD, and Hes1, a downstream target of
Notch.
Modifying the p53 pathway using drug combinations is an
attractive option. A combination of a CDK inhibitor andNutlin
was recently shown to synergize in the activation of p53 (42).
Perhaps combining acid domain-binding ligands with Nutlin
would also show a synergistic effect on the activation of p53 in
cancer cells. Therefore, targeting the acidic domain of MDM2
on its own or in combination with other drugs may be a useful
therapeutic strategy for the prevention of cancer, and the data
presented provides a good starting point for the design of pep-
tidomimetic inhibitors.
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